Is lactulose (a laxative) safe to use during breastfeeding in a lactating woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lactulose Safety During Breastfeeding

Lactulose is safe to use during breastfeeding and does not require interruption of nursing. The medication is not absorbed systemically and does not appear in breast milk, making it an appropriate first-line osmotic laxative for lactating women with constipation 1, 2.

Evidence-Based Safety Profile

FDA Drug Label Information

  • The FDA label states "It is not known whether this drug is excreted in human milk" and recommends caution when administering lactulose to nursing women 1
  • However, this conservative FDA statement reflects the lack of formal studies rather than evidence of harm—a common limitation in lactation safety data 3

Clinical Evidence Supporting Safety

  • Lactulose does not appear in breast milk because it is not absorbed in the small intestine, presenting no threat to the breastfed infant 2
  • A multicenter study of 62 pregnant women demonstrated that lactulose treatment can be safely continued during nursing without risk to the infant 2
  • The lack of systemic absorption is the key pharmacologic property that makes lactulose safe—it remains in the gastrointestinal tract and is not bioavailable to enter breast milk 2

Clinical Recommendations for Lactating Women

First-Line Treatment Approach

  • Lactulose is recommended as first-line therapy for chronic constipation during lactation, alongside macrogol (polyethylene glycol) 3
  • Macrogol may have some advantages over lactulose (faster onset, fewer flatulences), but both are considered safe and effective 3
  • The safest laxatives during breastfeeding are those that are not absorbed systemically and should be considered first-line therapy 4

Dosing and Administration

  • Standard dosing is 10-20 g (15-30 mL or 1-2 packets) daily, which may be increased to 40 g (60 mL or 2-4 packets) daily if needed 5
  • The most common maternal side effects are bloating and flatulence, which are dose-dependent and may limit use 6, 5

Important Clinical Caveats

When to Exercise Caution

  • Diabetic mothers: Lactulose contains galactose (<1.6 g/15 mL) and lactose (<1.2 g/15 mL), requiring caution in diabetic patients 1
  • Infants receiving lactulose directly (not via breast milk) may develop hyponatremia and dehydration, though this is not relevant to breastfeeding exposure 1

Alternative Options if Lactulose Not Tolerated

  • If maternal bloating or flatulence is problematic, consider polyethylene glycol (macrogol) as an alternative osmotic laxative 6, 3
  • Bulk-forming agents (psyllium, methylcellulose) are also safe due to lack of systemic absorption 6
  • Bisacodyl and sodium picosulfate can be used as second-line or rescue therapy during lactation 3

Drug Interactions to Monitor

  • Avoid concomitant use of other laxatives during initial therapy, as loose stools may falsely suggest adequate lactulose dosage 1
  • Non-absorbable antacids given concurrently may inhibit the desired pH drop in the colon, potentially reducing lactulose effectiveness 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.